1. Home
  2. RDNT vs EWTX Comparison

RDNT vs EWTX Comparison

Compare RDNT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RadNet Inc.

RDNT

RadNet Inc.

HOLD

Current Price

$60.67

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$41.46

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDNT
EWTX
Founded
1985
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
3.7B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
RDNT
EWTX
Price
$60.67
$41.46
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$82.80
$39.00
AVG Volume (30 Days)
844.5K
1.8M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,616,630,000.00
N/A
Revenue This Year
$22.78
N/A
Revenue Next Year
$10.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.05
N/A
52 Week Low
$50.79
$12.31
52 Week High
$85.84
$43.93

Technical Indicators

Market Signals
Indicator
RDNT
EWTX
Relative Strength Index (RSI) 60.81 63.27
Support Level $58.46 $29.03
Resistance Level $59.98 N/A
Average True Range (ATR) 2.86 2.59
MACD 0.55 0.67
Stochastic Oscillator 85.30 75.17

Price Performance

Historical Comparison
RDNT
EWTX

About RDNT RadNet Inc.

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: